期刊文献+

BRAF基因突变与皮肤黑色素瘤临床病理特征关系的meta分析

Relationship between BRAF mutations and clinicopathological features in cutaneous melanoma: a meta-analysis
原文传递
导出
摘要 目的探讨BRAF突变频率以及该突变与皮肤黑色素瘤(CM)临床病理特征的关系。方法使用Pubmed、Embase、维普、清华同方等数据库检索2013年4月以前相关文献,按纳入排除标准筛选文献,采用Revman5.0软件进行统计分析。结果涉及BRAF突变有9项研究,共1134例患者。CM患者BRAF突变率为47.3%。50岁以上患者BRAF突变OR=2.30,95%CI为1.36~3.91;浅表扩散性黑色素瘤(SSM)BRAF突变OR=2.11,95%CI为1.64~2.7l;病灶在躯干时BRAF基因突变OR=2.35,95%CI为1.71~3.21;浸润深度小于1mm时BRAF突变OR=1.56,95%CI为1.08~2.25。结论BRAF基因突变易发生于年龄50岁以上、SSM、病灶在躯干及浸润深度小于1mm的患者,而与性别无关。 Objective To explore the frequencies of BRAF mutations and the relationship between BRAF mutations and clinicopathological features of cutaneous melanoma (CM). Methods Pubmed, Embase, VIP, CNKI and other databases were utilized to search the relative articles and literatures were screened accord- ing to inclusion and excluding criteria and the meta-analysis was conducted by RevmanS. 0 software. Results Nine researches about BRAF mutations were enrolled in this study including 1134 patients. BRAF mutation rate of CM was 47.3%. As for patients over 50 years old, the OR of BRAF mutations was 2.30 (95% CI: 1.36- 3.91; the OR of BRAF mutations for superficial spreading melanoma (SSM) was 2. 11 (95% CI: !. 64- 2.71 ) ; the OR of BRAF mutations for lesions in the trunk was 2.35 (95% CI: 1.71-3.21 ) ; the OR of BRAF mutations for invasion depth less than 1 mm was f. 56 (95% CI: 1.08-2.25 ); Conclusion BRAF mutations are more frequent in patients over 50 years old, in SSM and in patients whose lesions locate in the truck and invasion depth less than 1 mm, but have no relationship with sex.
出处 《国际肿瘤学杂志》 CAS 2013年第10期797-800,共4页 Journal of International Oncology
基金 广西壮族自治区科学技术厅基金(桂科攻1140003B-86)
关键词 突变 黑色素瘤 META分析 BRAF Mutation Melanoma Meta-analysis BRAF
  • 相关文献

参考文献15

  • 1Moan J, Baturaite Z, Porojnicu AC, et al. UVA, UVB and incidence of cutaneous malignant melanoma in Norway and Sweden. Photochem Photobiolol Sci, 2012, 11(1) : 191-198.
  • 2Haneke E. Ungual melanoma-controversies in diagnosis and treatment. Dermatol Ther, 2012, 25 ( 6 ) : 510 -524.
  • 3Libra M, Malaponte G, Navolanic PM, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle, 2005, 4 (10) : 1382-1384.
  • 4Edlundh-Rose E, Egyh6zi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res, 2006, 16(6) : 471-478.
  • 5Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol, 2006, 126(1) : 154-160.
  • 6Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res, 2006, 16 (4) : 267 -273.
  • 7Saldanha G, Potter L, Daforno P, et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res, 2006, 12(15): 4499-4505.
  • 8Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF( T1799A(V600E) ) mutation in primary melanoma. J Invest Dermatol, 2006, 127(4) : 900-905.
  • 9Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prey, 2007, 16(5 ) : 991-997.
  • 10Kannengiesser C, Spatz A, Michiels S, et al. Gene expression signa- ture associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol, 2008, 1 (4) : 425-430.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部